CAPR · Capricor Therapeutics, Inc. · Webcasts, Transcripts & Audio
$6.61
-0.04 (-0.60%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$384.30M
Shares
58.14M
Volume · Oct 20
2.05M
Avg daily vol (3M)
7M
Capricor Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Capricor Therapeutics, Inc. (CAPR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q2
2026-08-13
Capricor Therapeutics, Inc. (CAPR) Q2 2026 Earnings Call Transcript
Balanced tone
Regulatory pathway and BLA amendment
FDA Advisory Committee outcome
Commercial readiness and manufacturing
Diluted EPS
$-0.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-10
Capricor Therapeutics, Inc. (CAPR) June 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-12
Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript
Confident tone
Commercial readiness and launch planning
BLA regulatory path and HOPE-3 data
Litigation against NS Pharma / Nippon Shinyaku
Diluted EPS
$-0.59
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Capricor Therapeutics, Inc. (CAPR) Q4 2025 Earnings Call Transcript
Confident tone
Deramiocel for DMD cardiomyopathy
HOPE-3 Phase 3 trial data
DVA patient-reported outcome (EAT 10 BITE)
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-03-11
Capricor Therapeutics, Inc. (CAPR) March 11, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-10
Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript
Confident tone
HOPE-3 Phase 3 readout
Regulatory pathway and CRL response
Manufacturing and CMC
Diluted EPS
$-0.54
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Call Transcript
Positive tone
Deramiocel for DMD Cardiomyopathy
FDA Complete Response Letter and Regulatory Path
HOPE-3 Phase 3 Trial and Endpoint Change
Diluted EPS
$-0.57
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Capricor Therapeutics, Inc. (CAPR) Q1 2025 Earnings Call Transcript
Confident tone
BLA Approval and FDA Process
HOPE-2 and HOPE-3 Clinical Data
Label and Patient Identification
Diluted EPS
$-0.53
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-19
Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript
Confident tone
BLA Submission and Regulatory Progress
Safety and Efficacy Data
Commercial Launch Readiness
Revenue
$11.13M*
▼ 7.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-16
Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript
Confident tone
BLA Submission for DMD Cardiomyopathy
Ex-US Licensing and Partnerships
Patient Population and Reimbursement
Revenue
$2.26M
▼ 63.4% YoY Diluted EPS
$-0.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Capricor Therapeutics, Inc. (CAPR) Q2 2024 Earnings Call Transcript
Confident tone
Deramiocel BLA submission and FDA pathway
StealthX exosome platform pipeline
Nippon Shinyaku partnership and milestones
Revenue
$3.97M
▲ 1.4% YoY Diluted EPS
$-0.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Capricor Therapeutics, Inc. (CAPR) Q1 2024 Earnings Call Transcript
Confident tone
HOPE-3 Phase 3 Trial and CAP-1002 for DMD
Manufacturing and CMC (San Diego facility, potency assays)
Regulatory progress with FDA (BLA readiness)
Revenue
$4.91M
▲ 64.3% YoY Diluted EPS
$-0.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Capricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call Transcript
Confident tone
BLA readiness, regulatory pathway, and FDA interactions
Phase III HOPE-3 pivotal trial progress and interim results
Financial position, milestones, and runway
Revenue
$12.09M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Capricor Therapeutics, Inc. (CAPR) Q3 2023 Earnings Call Transcript
Revenue
$6.19M
▲ 288.7% YoY Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Capricor Therapeutics, Inc. (CAPR) Q2 2023 Earnings Call Transcript
Revenue
$3.92M
Diluted EPS
$-0.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Capricor Therapeutics, Inc. (CAPR) Q1 2023 Earnings Call Transcript
Revenue
$2.99M
Diluted EPS
$-0.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-15
Capricor Therapeutics, Inc. (CAPR) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Capricor Therapeutics, Inc. (CAPR) Q3 2022 Earnings Call Transcript
Revenue
$1.59M
Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Capricor Therapeutics, Inc. (CAPR) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Capricor Therapeutics, Inc. (CAPR) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.32
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Capricor Therapeutics, Inc. (CAPR) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Capricor Therapeutics, Inc. (CAPR) Q3 2021 Earnings Call Transcript
Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Capricor Therapeutics, Inc. (CAPR) Q2 2021 Earnings Call Transcript
Revenue
$204,082
▲ 309.3% YoY Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Capricor Therapeutics, Inc. (CAPR) Q1 2021 Earnings Call Transcript
Revenue
$40,816
▼ 78% YoY Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-11
Capricor Therapeutics, Inc. (CAPR) Q4 2020 Earnings Call Transcript
Revenue
$57,830*
▼ 74% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q2
2020-08-06
Capricor Therapeutics, Inc. (CAPR) Q2 2020 Earnings Call Transcript
Revenue
$49,864
▼ 87.8% YoY Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-14
Capricor Therapeutics, Inc. (CAPR) Q1 2020 Earnings Call Transcript
Revenue
$185,693
▼ 19.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-18
Capricor Therapeutics, Inc. (CAPR) Q4 2019 Earnings Call
Revenue
$222,100*
▼ 65.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 webcasts
Key facts
CIK
1133869
CUSIP
14070B309
13F (30d)
10 filings
10 filers
Visit website
Investor relations